C60 fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237293/
J Nanobiotechnology. 2017; 15: 8.
Published online 2017 Jan 13. doi: 10.1186/s12951-016-0246-1
PMCID: PMC5237293
PMID: 28086894
C60 fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue
Yurij I. Prylutskyy,1 Inna V. Vereshchaka,2 Andriy V. Maznychenko,corresponding author2 Nataliya V. Bulgakova,2 Olga O. Gonchar,3 Olena A. Kyzyma,1,4 Uwe Ritter,5 Peter Scharff,5 Tomasz Tomiak,6 Dmytro M. Nozdrenko,1 Iryna V. Mishchenko,7 and Alexander I. Kostyukov2
Author information Article notes Copyright and License information Disclaimer
This article has been cited by other articles in PMC.
Conclusions
C60FAS leads to reduction in the recovery time of the muscle contraction force and to increase in the time of active muscle functioning before appearance of steady fatigue effects. Therefore, it is possible that C60FAS affects the prooxidant-antioxidant muscle tissue homeostasis, subsequently increasing muscle endurance.